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The c-Myc protein is dysregulated in many human cancers and its function has not been fully 
elucitated yet. The c-Myc inhibitor Omomyc displays potent anticancer properties in animal 
models. It perturbs the c-Myc protein network, impairs c-Myc binding to the E-boxes, retaining 
transrepressive properties and inducing histone deacetylation. Here we have employed Omomyc to 
further analyse c-Myc activity at the epigenetic level. We show that both Myc and Omomyc stimulate 
histone H4 symmetric dimethylation of arginine (R) 3 (H4R3me2s), in human glioblastoma and 
HEK293T cells. Consistently, both associated with protein Arginine Methyltransferase 5 (PRMT5)—the 
catalyst of the reaction—and its co-factor Methylosome Protein 50 (MEP50). Confocal experiments 
showed that Omomyc co-localized with c-Myc, PRMT5 and H4R3me2s-enriched chromatin 
domains. Finally, interfering with PRMT5 activity impaired target gene activation by Myc whereas 
it restrained Omomyc-dependent repression. The identification of a histone-modifying complex 
associated with Omomyc represents the first demonstration of an active role of this miniprotein 
in modifying chromatin structure and adds new information regarding its action on c-Myc targets. 
More importantly, the observation that c-Myc may recruit PRMT5-MEP50, inducing H4R3 symmetric 
di-methylation, suggests previously unpredictable roles for c-Myc in gene expression regulation and 
new potential targets for therapy.
Dysregulation of c-Myc—a basic helix-loop-helix/leucine zipper (bHLH-Zip) transcriptional regulator 
that controls a variety of normal cellular functions1—is a major mechanism of tumorigenesis. Abnormal 
levels of Myc (c-, N-, L-Myc) proteins are strongly associated with a variety of human cancers. c-Myc—
hereafter named Myc—dimerizes with another member of the same family, Max; the heterodimer binds 
DNA with maximum selectivity for the E-box sequence CACGTG. Myc also interacts with a large num-
ber of proteins and multicomponent complexes involved in the regulation of transcription and chromatin 
structure. Unlike the majority of transcription factors, it does not stimulate transcription initiation; rather 
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it enhances the production of transcripts from already active genes2–4, usually by promoting transcription 
elongation. It is still debated whether Myc directly represses a critical set of target genes or repression 
results from induction of factors like EZH2, a component of the Polycomb repressive complex5,6.
Myc represents an established target for cancer treatment, as demonstrated by studies in animal 
models, by drugs that mostly affect Myc transcription like JQ17 and by Myc dominant negatives such 
as Omomyc, a ninety amino acid long, mutant bHLH-Zip domain8–10 that affects Myc function at the 
level of protein interactions and DNA binding11. Omomyc retains Myc transprepressive properties and 
displays high therapeutic efficacy in a variety of transgenic models—lung carcinoma12, SV40-driven pan-
creatic insulinoma13, glioma14—while being well tolerated for an extended period of time12. A further 
clarification of how Omomyc works at the cellular and mechanistic level in cancer cells is very relevant 
for developing strategies or designing small molecules able to interfere with Myc for cancer therapy.
Glioblastoma multiforme (GBM; WHO grade IV astrocytoma) is the most common and aggressive 
brain tumour in the adult, usually fatal in about 15 months15. GBM has the propensity to infiltrate, 
making complete surgical resection impossible, has a very heterogeneous cellular composition, and is 
largely resistant to radiation and chemotherapy15. This latter feature appears to depend on rare fractions 
of self-renewing, multi-potent cells able to proliferate and give origin to neuroepithelial lineages, named 
tumor initiating cells (TICs) or glioblastoma stem cells (GSCs)16. GSCs are capable of repopulating the 
tumour after treatment16 and are believed to be responsible for tumour progression and recurrence. Like 
other cancer stem cells, GSCs usually present Myc network activation17, which is required for GSC pool 
maintenance in vitro and tumorigenic potential in vivo18.
Dysregulation of epigenetic mechanisms is a distinct feature of cancer. In particular, both DNA and 
histone methylation profiles have been found to be altered in many tumours19,20. Histone methylation 
may occur at lysine (K) or arginine (R) residues. Histone R methylation has been less investigated than 
histone K methylation so far. However, growing evidences indicate protein arginine methyltransferases 
(PRMTs) as misregulated in cancer. PRMTs belong to the largest class (class I) of S-adenosylmethionine 
(AdoMet)-dependent methyltransferase enzymes and are further divided into 4 types, according to their 
methylation pattern (Wolff, 2009)21. PRMT5 is able to mono-methylate or symmetrically di-methylate 
non-histone and histone proteins20–22, being the latter usually repressive of transcription. PRMT5 expres-
sion and activity were found to be dysregulated in many tumors20; more recent data indicate PRMT5 
as an important player in glioblastoma pathogenesis. Indeed, PRMT5 expression correlates with glioma 
malignant grade and is inversely related to patient survival23,24. Consistently, PRMT5 knock out decreases 
the proliferation rate of glioblastoma cells as well as their survival and migratory capacity24.
In the present work we show that Myc and Omomyc induce a pronounced, genome-wide, increase 
in PRMT5-dependent symmetric di-methylation of R3 on histone H4 (H4R3me2s), in 293T and glio-
blastoma cells. Consistently, Myc and Omomyc associated with the PRMT5-Methylosome 50 (MEP50)25 
complex. Co-localization experiments confirmed the spatial overlapping of Omomyc, PRMT5, and Myc 
with H4R3me2s enriched chromatin regions. Further, inhibiting PRMT5 activity in the nucleus rescued 
Omomyc-dependent transcriptional repression of Myc target genes and impaired their activation by Myc.
Altogether, these data underpin a novel, unpredictable, PRMT5-based regulatory mechanism under-
lying Myc-dependent transcription. Further, they provide new information about Omomyc function at 
the molecular and epigenetic levels.
Results
Myc and Omomyc induce symmetric di-methylation of arginine 3 (R3) of histone H4. Omomyc 
expression results in a marked deacetylation of lysine 9 (K9) on histone H3 (H3K9Ac) in Rat1 cells11. 
To further investigate the epigenetic effects of Myc inhibition by Omomyc in glioblastoma cells, we 
analysed the expression of several histone modifications upon Omomyc induction by doxycycline in 
U87MG cells infected with a lentivirus encoding a Flag-Omomyc (FO; U87MG/FO) fusion protein. We 
found that H3K9 histone acetylation decreased as expected. Among the other modifications tested, we 
observed an increase in H4R3me2s, which paralleled Omomyc expression (Fig. 1A). The same result was 
obtained in patient-derived glioblastoma stem cells BT168/FO and BT275/FO (Fig.  1B,C). To further 
validate these data and evaluate whether this epigenetic function was shared by Myc and Omomyc, we 
ectopically expressed Flag-Omomyc and Flag-Myc proteins in HEK293T cells, and analysed H4R3me2s 
by Western blot. We found that Flag-Omomyc and Flag-Myc induced H4R3me2s (Fig. 1C). This result 
attributes a specific role to Myc in regulating H4R3 symmetric di-methylation. Moreover, by immuno-
fluorescence, we found that Flag-Omomyc and Flag-Myc expressing HEK293T cells were highly positive 
for H4R3me2s (Fig. 1D), compared to controls. Altogether, these results ascribe a specific role to Myc in 
regulating H4R3 symmetric di-methylation, a role that is maintained by Omomyc.
Myc and Omomyc interact with PRMT5. Symmetric di-methylation of R3 on H4 is 
PRMT5-dependent. Therefore, we performed immunoprecipitation experiments, both in glioblastoma and 
HEK293T cells, to assess PRMT5 recruitment by Myc and Omomyc. A series of reciprocal immunoprecip-
itations, shown in Fig. 2A, revealed the formation of the same complex when U87MG/FO protein extracts 
were immuno precipitated with either anti-Flag, anti-PRMT5 or anti-Myc antibodies. BT168 cells present 
a high level of Myc (not shown). Therefore, immunoprecipitation experiments were also performed in 
this cell line by using the Myc antibody. As shown in Fig.  2B, Myc, Omomyc, and PRMT5 were found 
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to be associated in BT168/FO cells as well. Similar results were obtained in HEK293T/FO cells (Fig. 2C). 
To further confirm these data, HEK293T cells were transiently co-transfected with 6myc-tagged PRMT5 
and Flag-Omomyc expression vectors and immunoprecipitation were performed 48 hrs after transfection 
with an anti-Flag antibody. As shown in Fig. 2D, a sharp interaction between Omomyc and PRMT5 was 
found in HEK293T cells transfected with both plasmids.
Omomyc co-localizes with Myc, PRMT5 and H4R3me2s-enriched chromatin domains in 
U87MG cells. Co-localization between Omomyc, Myc, PRMT5 and H4R3me2s-enriched chromatin 
regions was evaluated by confocal analyses in U87MG/FO cells upon doxycycline treatment. Figure  3 
shows an almost complete overlap between Omomyc—revealed by Flag antibody—and either PRMT5, 
H4R3me2s or Myc. Intriguingly, panel A shows that PRMT5 presented a diffuse cellular localization in 
untreated cells (see inset 1). Conversely, as long as Omomyc was expressed, PRMT5 clearly was placed 
in the nucleus (inset 2). Western blot analyses on fractionated cells extracts confirmed this observa-
tion (Supplementary Fig. S1). Myc co-localized with Omomyc in the nucleus, as expected (Fig.  3B). 
Importantly, Fig. 3C and supplementary Fig. S2 show that symmetric di-methylation of R3 on histone 
H4 paralleled Omomyc expression in both U87MG/FO and BT168/FO cells. In U87MG and BT168 wild 
type cells, cultured in the presence of doxycycline, no changes in symmetric di-methylation of R3 on his-
tone H4 were found (Supplementary Figures S2 and S3). These data further validate Omomyc association 
with PRMT5 and confirm the ability of Omomyc to induce H4R3 symmetric di-methylation, presumably 
by recruiting a PRMT5-MEP50-containing complex.
Figure 1. Omomyc and Myc-dependent H4R3 symmetric di-methylation. (A) Western blot analysis of 
U87MG/FO cell extracts along a time course between 3 and 24 hrs after doxycycline treatment. Picture 
shows the global changes of several histone modifications upon Omomyc expression. H3K9 histone 
acetylation decreased, as expected. H3K27 tri-methylation slightly decreased, as well. On the contrary, a 
peak of K4 tri-methylation on histone H3 was observed after 8 hrs of doxycycline treatment. The increase 
in H4R3 symmetric di-methylation followed the kinetic of expression of Flag-Omomyc. (B) Western blot 
analysis of BT168/FO and BT275/FO cell extracts along a time course between 3 and 48 hrs after doxycycline 
treatment. H4R3me2s increased in parallel with Flag-Omomyc. (C) Western blot analysis of nuclear 
extracts from HEK293T cells transfected with Flag-Omomyc and Flag-Myc encoding vectors. H4R3me2s 
was induced upon both Omomyc and Myc expression. The empty vector was used as control. (D) Double 
immunofluorescence. HEK293T cells transfected with either Flag-Omomyc or Flag-Myc enconding vectors 
were stained simultaneously with anti-H4R3me2s and anti-Flag antibodies. HEK293T cells expressing either 
Flag-Omomyc or Flag-Myc were also positive for H4R3me2s. These results are representative of at least three 
independent experiments.
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Inhibition of PRMT5 nuclear activity impairs target gene activation by Myc and repression 
by Omomyc. PRMT5 catalytic activity in the nucleus requires at least two co-factors, the methy-
losome protein 50 (MEP50)25, associated with PRMT5 both in the cytoplasm and nucleus, and the 
cooperator of PRMT5 (COPR5)26, which selectively sustains PRMT5 nuclear function. Since PRMT5 
shRNAs were ineffective to knock down PRMT5 transcripts, we used shRNAs against COPR5 to trans-
fect HEK293T/FO cells, harbouring an inducible Omomyc. Real time PCR experiments were performed 
to evaluate the expression level of two target genes activated by Myc: carbamoyl-phosphate synthase 
aspartatecarbamoyltransferase-dihydroorotase27 (cad) and cyclin D1 (cycD1)28. Upon Omomyc induc-
tion, we observed a 30% inhibition of cad and cycD1 expression, which was recovered by co-transfection 
of shCOPR5 (Fig.  4A). This suggests that PRMT5 might be one of the molecules involved in 
Omomyc-dependent repression of these Myc activated genes. Moreover, ChIP experiments indicated 
a local enrichment of H4R3me2s histone residues at Omomyc-bound upstream chromatin domains of 
cycD1 and nucleolin (Ncl) gene promoters (Supplementary Fig. S4). We asked whether PRMT5 inhi-
bition by shCOPR5 might affect Myc activation of the two targets and transfected HEK293T cells with 
plasmids expressing Myc and shCOPR5. We found that Myc transactivated cad and cycD1, as expected. 
Cotransfection of shCOPR5, instead, impaired transactivation by Myc (Fig. 4B).
These data strongly suggest that PRMT5 methylase complex and H4R3 symmetric di-methylation 
may modulate Myc activity at the epigenetic level, possibly by facilitating transactivation. Recruitment 
of the same methylase complex by Omomyc appeared, instead, associated with Omomyc-dependent 
transrepression of Myc targets, possibly by supporting deacetylation (Ref. 11 and Fig. 1A) and chromatin 
compaction.
Figure 2. Omomyc and Myc associate to the PRMT5-MEP50 complex. (A) Immunoprecipitation 
experiments. Cell extracts from U87MG/FO cells—cultured in the presence or absence of doxycycline for 
24 hrs—were immunoprecipitated with either anti-Flag, anti-PRMT5 or anti-Myc antibodies. Flag-Omomyc, 
PRMT5, MEP50 and Myc were detected by subsequent western blot analyses. Flag-Omomyc recruited 
PRMT5-MEP50 and Myc proteins. Consistently, PRMT5-MEP50 recruited both Flag-Omomyc and Myc. 
Immunoprecipitation with the anti-Myc antibody was less efficient; however, Flag-Omomyc and PRMT5-
MEP50 were still detected. (B) Immunoprecipitation from BT168/FO cell extracts after 8 and 24 hrs of 
doxycycicline treatment. The anti-Myc antibody was used. PRMT5-MEP50, Flag-Omomyc and Myc were 
found associated also in this cell line. (C) Immunoprecipitation experiments from HEK293T/FO cell 
extracts. Either Anti-Flag or anti-PRMT5 antibodies were used. In both the experiments, Flag-Omomyc, 
PRMT5-MEP50 and Myc were found associated. (D) Immunoprecipitation experiments from HEK293T cell 
extracts transiently co-tranfected with both PRMT5-6myc and Flag-Omomyc (FO) vectors. The Flag-Red 
(FR) vector was used as control. PRMT5 was found specifically associated to Flag-Omomyc. Abbreviations: 
TOT = total extracts; NL = nuclear extracts; IP = immunoprecipitate. All these results are representative of at 
least four independent experiments.
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Discussion
PRMT5 plays a key role in a wide variety of cellular processes, including developmental pathways—
such as neurogenesis29 and myogenesis30—metabolic responses31, somatic cell reprogramming32, and 
genome defense at the preimplantation stage33. In the cytoplasm, PRMT5 is involved in multiple func-
tions, such as the regulation of Golgi apparatus34, ribosome biogenesis35, maintenance of pluripotency 
in embryonic stem cells36, neuronal spreading and migration37. PRMT5 acts in concert with a number 
of proteins involved in the epigenetic regulation of chromatin structure (for a comprehensive review 
see Karkhanis et al., 2011)38. Several transcription factors interact with PRMT527,39,40. Further, PRMT5 
associates with N-Myc in neuroblastoma cells, promoting its stability, presumably by methylating a spe-
cific arginine (R242)41. However, no effect of the N-Myc/PRMT5 complex, either at epigenetic or at 
the transcription level, was reported. In the present study, we show that, in GBM cells, either U87MG 
or GSCs, as well as in HEK293T cells, Myc and Omomyc induce symmetrical H4R3 di-methylation 
(Fig.  1A–C). This effect correlates with the local enrichment of H4R3me2s histones and Omomyc at 
the chromatin domains upstream of Myc target gene promoters (Supplementary Fig. S4). In this view, 
Omomyc appears to simply retain a function of Myc. However, high levels of Myc and PRMT5 corre-
late with malignancy23,38, while Omomyc harbours anti-cancer properties. Thus, it is conceivable that, 
although associating both with PRMT5, the functional effect may be different. Indeed, inhibition of 
PRMT5 activity by a shRNA against its co-factor COPR5 restrained Myc transactivating properties, while 
recovered Omomyc-dependent repression of Myc targets (Fig.  4). PRMT5 interacts with a number of 
epigenetic enzymes involved in either activation or inhibition of transcription. It was recently associated 
to the activation of transcription of adipogenic genes, through H3R8 symmetric di-methylation and 
SWI/SNF chromatin-remodeling enzyme recruitment42. PRMT5-mediated symmetric di-methylation 
of H3R2 keeps genes poised for transcriptional activation22. Further, PRMT5 interacts with mSin3A/
histone deacetylase (HDAC) complex30 and its activity mediates DNA methyltransferase 3a (Dnmt3a) 
Figure 3. Omomyc co-localization with PRMT5, Myc and H4R3me2s-enriched chromatin regions in 
U87MG/FO cells. Confocal analyses showing an almost complete overlay between Flag-Omomyc, PRMT5 
(A), c-Myc (B) and H4R3me2s (C) in U87MG/FO cells. Images are representative of at least 10 fields 
analyzed.
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binding and subsequent DNA methylation of H4R3me2s rich chromatin regions43. Restraining PRMT5 
nuclear activity led to a recovery of Myc inhibition by Omomyc, suggesting that Omomyc may silence—
at least in part—Myc target genes11 through PRMT5 recruitment and H4R3 symmetric di-methylation. 
At genomic level, Omomyc occupies Myc binding sites (Galardi et al., submitted). Moreover, Omomyc 
globally induces histone deacetylation (Fig. 1A) while Myc promotes acetylation44. These findings sug-
gest that complexes associated with either Myc or Omomyc on chromatin, although involving PRMT5 
in both cases, may have a different activity. Further experiments are required to clarify these aspects. 
Indeed, both PRMT5 and Myc expression correlate with tumour malignancy23,38,3 and PRMT5 stabilizes 
N-Myc41 in neuroblastoma. We consistently found an association between Myc or Omomyc and PRMT5 
in glioblastoma cells (Fig.  2). Based on this finding, we propose that Omomyc may perturb the Myc/
PRMT5 interaction and that this may have a role in its potent anti-oncogenic properties.
A PRMT1/PRMT5/MEP50 containing complex was found to be associated with the Chromatin 
Target of PRMT1 (CHTOP) protein in glioblastoma cells and to play a critical role in the activation of 
cancer-related genes45. Thus, it is possible that Omomyc may affect the PRMT1/PRMT5/MEP50/CHTOP 
complex, impairing cancer-related gene expression.
PRMT5 is present both in the cytoplasm and in the nucleus of cancer cells. Its cytosolic locali-
zation has been associated with a high grade of malignancy. Indeed, cytoplasmic PRMT5 correlates 
with a poor prognosis in prostate46, melanoma47 and lung cancers48. In GBM cells, PRMT5 showed a 
preferential nuclear localization, although a sizeable fraction was distributed in the cytoplasm as well; 
interestingly, PRMT5 apparently localizes exclusively in the nucleus of normal neuronal cells23,29. Upon 
Omomyc induction, PRMT5 was present almost exclusively in the nucleus, where it co-localized with 
Myc, Omomyc, and H4R3me2s-enriched chromatin regions (Fig.  3). This data was further confirmed 
by western blot on fractionated cell extracts. In this context, Omomyc may represent a nuclear shuttle 
for PRMT5, eliminating the residual cytoplasmic amount, which may contribute to GBM tumorigenesis.
Altogether, these data report a newly identified functional interaction between Myc and PRMT5, 
adding to Myc a new layer of regulation at the epigenetic level. Further investigations are required to 
understand the biological significance of this association, which may envisage small molecule-based 
epigenetic therapies for GBM. Further, they suggest a PRMT5-based molecular mechanisms supporting 
Omomyc function as a transcriptional repressor of Myc target genes in GBM.
Figure 4. Interfering with PRMT5 nuclear activity restrained Omomyc-dependent repression and impairs 
activation of Myc targets (A) HEK293T/FO cells. CycD1 and cad gene expression was repressed for a 30% 
upon Omomyc induction. Their expression was almost completely recovered by Inhibiting PRMT5 through 
the ectopic expression of shCOPR5. (B) HEK293T wild type cells. Myc ectopic expression increased CycD1 
and cad mRNA levels. The presence of shCOPR5, but not of a scrambled shRNA vector, weakened Myc-
dependent cycD1 and cad activation.
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Material and Methods
Cell culture and treatment. Patient-derived brain tumor 168 (BT168) and brain tumor 275 stem 
cells (BT275) were cultured as described49. U87MG (ATCC-HTB14) and HEK293T cells were cultured in 
Dulbecco’s Modified Eagle Medium (DMEM, SIGMA, St. Louis, Mo, USA), supplemented with 10% Fetal 
Bovine Serum (FBS, Thermo Fisher Scientific, Waltham, MA, USA), 2 mM Glutammine and penicillin/
streptomycin/amphotericin B (Thermo Fisher Scientific). To induce Omomyc expression, 0.25 μ g/ml of 
doxycycline (SIGMA) were used.
Lentiviral infection. U87MG/FlagOmomyc (FO), BT168/FO, BT275/FO and HEK293T/FO cells 
were all obtained by lentiviral transduction. Viral particles were produced in HEK293T cells by transient 
transfection using Lipofectamine 2000 reagent (Thermo Fisher Scientific). 2 × 106 cells were cotrans-
fected with 4 μ g of pSLIK-FlagOmomyc, 2 μ g each of the second-generation packaging plasmids PLP1 
and PLP2 and 1 μ g of the vesicular stomatitis virus (VSV) G envelope plasmid pMD VSV-G diluted 
in Opti-MEM (Thermo Fisher Scientific). The medium was removed after 12–16 h and replaced with 
4 ml of fresh growth media. Supernatants were collected every 24 hr between 48 to 72 hr after transfec-
tion, pulled together and concentrated by ultracentrifugation in a Beckman SW-28 rotor for 2 hours at 
25000 rpm, 4 °C. For lentiviral infection, 2–5 × 105 cells were seeded in 35 mm dishes and infected the 
following day in cell culture medium containing 4 μ g/ml polybrene. To generate stable inducible lines, 
cells were selected for two weeks with 50–200 μ g/ml Hygromycin B (SIGMA). After selection, induction 
of FLAG-Omomyc expression by 0.25 μ g/ml doxycycline (SIGMA) was assessed by both immunocyto-
chemistry and western blotting.
Plasmids and transfections. The Flag-Omomyc insert was excised from pCbsFlag-Omomyc 
plasmid with BamHI and HindIII restriction enzymes and inserted into pLNCX2 (Clontech, 
Saint-Germain-en-Laye France) using BglII-HindIII restriction sites. Flag-Myc was excised from the 
pCbsFlag-Myc vector and inserted in pLPCX (Clontech) in BamHI-ClaI restriction sites. The PRTM5 
coding sequence was obtained from a human cDNA library by PCR amplification, and inserted in pCS2 
vector50. pRFP-C-RS plasmid expressing a COPR5 specific shRNA sequence (shCOPR5) and the rela-
tive scrambled control were purchased by OriGene (Origene, Rockville, MD, U.S.A). Transfections were 
performed by using Lipofectamine 2000 (Thermo Fisher Scientific) according to the manufacturer’s 
instructions.
Acid extraction of histones. Cells were lysed in 10 mM Hepes pH 7.9, 10 mM KCl, 0.2 mM EDTA, 
1 mM DTT, 0.6% Nonidet-P40 and protease/phosphatase inhibitors cocktails (SIGMA). Lysates were 
incubated 15 minutes on ice and centrifuged at 10000 rpm for 10 minutes at 4 °C. The cytoplasmic frac-
tion was recovered and stored at − 80 °C. The nuclear pellet was resuspended in 20 mM Hepes pH 7.9, 
0.4 M NaCl, 2 mM EDTA, 1 mM DTT and protease/phosphatase inhibitors cocktails. Samples were incu-
bated on ice for 30 minutes and centrifuged at 13000 rpm for 10 minutes. The supernatant containing 
nuclear proteins was stored at –80 °C. The remaining pellet, containing DNA and proteins tightly asso-
ciated, was washed in 10 mM NaCl, 10 mM Tris-HCl pH 7.5, 1.5 mM MgCl2 and finally resuspended 
in the same washing buffer added with 0.4N HCl to obtain HCl soluble proteins. Samples were incu-
bated for at least 1 hour at 4 °C and the day after were centrifuged at 10000 rpm for 20 minutes at 4 °C. 
Supernatant was recovered and the acid-soluble proteins were precipitated with 10 volumes of acetone, 
over night (O/N) at − 20 °C. The day after, samples were centrifuged at 10000 rpm for 20 minutes at 4 °C. 
Precipitated HCl-soluble proteins were resuspended in sterile H2O and stored at − 20 °C.
Fractionated cell extracts. Fractionated cell extracts were performed as described51.
Immunoprecipitation. For immunoprecipitation experiments, cells were lysed in 10 mM Hepes pH 
7.9, 50 mM NaCl, 500 mM Sucrose, 0.1 mM EDTA, 0.5% Nonidet-P40, 5 mM MgCl2, 1 mM DTT and 
protease/phosphatase inhibitors cocktails. Samples were incubated on ice for 30 minutes and centrifuged 
at 8000 rpm at 4 °C. The cytoplasmic faction was recovered and stored on ice. Nuclei were resuspended 
in 20 mM Hepes pH 7.9, 0.42 M NaCl, 25% Glycerol, 0.2 mM EDTA, 1.5 mM MgCl2, 0.5 mM DTT 
and protease/phosphatase inhibitors cocktails. Samples were vortexed for 10 seconds and centrifuged 
for 5 minutes at 14000 rpm at 4 °C. Supernatants containing nuclear proteins were recovered, mixed 
with the previously collected cytoplasmic fraction and the mixture underwent immunoprecipitation. 
At least 1 mg of extract was used for each experiment. Immunoprecipitation was performed by using 
either ImmunoCruzF or C system (Santa Cruz Biotechnologies, Santa Cruz, CA, USA), according to the 
manufacturer’s instructions.
Western blot. Proteins were resolved in 12% polyacrilammide gels and blotted onto nitrocellulose 
filters (GE Heath Care, Little Chafont, Buckinghamshire, UK) for 2 hours at 250 mA on ice. Filters were 
blocked in phosphate buffered saline plus 0.1% Tween-20 (PBST, SIGMA) added with 10% non-fat dry 
milk, for 1 hour at room temperature (RT). Primary antibodies were incubated O/N at 4 °C, according 
to the concentration recommended by the manufacturer, in PBST plus 2.5% non-fat dry milk. After 
three 5 minutes washes, filters were incubated for 1 hour at RT with either goat-anti rabbit (1:5000) 
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or goat-anti mouse (1:2000) horseradish peroxidase (HRP)-conjugated secondary antibodies (Merck 
Millipore, Darmstadt, Germany), or with ImmunoCruz F or C detection reagent, in the case of immu-
noprecipitated proteins, in PBST plus 2.5% non-fat dry milk. Proteins were revealed by SuperSignal West 
Pico Chemiluminescent Substrate (Thermo Fisher Scientific). Images were captured with a Chemidoc 
XRS+ (Bio-Rad, Hercules, CA, USA).
Anti-H4R3me2s, anti-MEP50 and anti-PRMT5 antibodies were from Abcam (Abcam, Cambridge, 
UK); anti-Flag and anti-H3 antibodies were from SIGMA. Anti-H3K4me3, anti-H3K27me3 and 
anti-H3K9Ac antibodies were from Merck-Millipore. Anti-Myc and anti-TATA Binding Protein (TBP) 
were from Santa Cruz Biotechnologies.
Immunofluorescence. Immunofluorescence analysis on U87MG cells was performed as described11. 
Immunofluorescence on BT168 cells, grown as neurospheres, was performed as follows. Neurospeheres 
were centrifuged for 20 minutes at 400 rpm, washed in PBS 1X and centrifuged again for 5 minutes 
at 800 rpm. Cells were transferred to a microcentrifuge tube and fixed in 4% paraformaldheyde 
for 15 minutes at RT. Thereafter, neurospheres were centrifuged for 5 minutes at 800 rpm and autoflu-
orescence was quenched with 25 mM Glycine in PBS 1X, pH 7.4, for 5 minutes. After two washes in 
PBS 1X, neurospheres were permeabilized with 0.3% Triton X-100 in PBS 1X for 5 minutes and washed 
with PBS/0.1% Tween-20. Blocking was in 10% BSA in PBS 1X, for either 1 hr at RT or O.N. at + 4 °C. 
After a 5 minutes centrifugation at 800 rpm, primary antibodies were added in blocking solution O.N. 
Neurospheres were washed twice in PBS/0.1%Tween-20. Secondary antibodies were added in block-
ing solution for 1 hr. After two washes in PBS/0.1%Tween-20, neurospheres were counterstained with 
DAPI (1 μ g/ml) in PBS 1X for 5 minutes and washed again in PBS/0.1% Tween-20. Supernatant was 
carefully removed and Neurospheres were resuspended in phosphate-buffered glycerol. Neurospheres 
were spotted onto microscope slides by using 20 μ l pipette tips, cut to avoid neurospheres disrup-
tion. Secondary antibodies were: donkey-anti mouse AlexaFluor488 and goat-anti rabbit AlexaFluor555 
(Thermo Fisher Scientific).
Confocal analysis. Confocal analysis was performed as described51. Secondary antibodies were: 
donkey-anti mouse AlexaFluor488 and goat-anti rabbit AlexaFluor555 (Thermo Fisher Scientific).
shRNA and real time PCR. shCOPR5 and scrambled control vector were transfected in 
HEK293T/FO by using Lipofectamine 2000 reagent (Thermo Fisher Scientific) according to the manu-
facturer’s instructions. Where indicated, HEK293T cells were treated for additional 16 hours with doxy-
cycline. Total RNA was extracted by using TRIZOL reagent (Thermo Fisher Scientific) according to the 
manufacturer’s instructions. Reverse transcription reaction was performed by using M-MLV Reverse 
Transcriptase kit (Promega, Madison, WI, U.S.A). Expression levels of Omomyc target genes were ana-
lysed using SYBR Green- based Real Time RT-PCR (Thermo Fisher Scientific). Primers were:
hTBP F 5′ tgc ccg aaa cgc cga ata taa tc 3′ 
hTBP R 5′ tgg ttc gtg gct ctc tta tcc tc 3′ 
hCOPR5 F 5′ gga gct gtc aga agg gac aa 3′ 
hCOPR5 R 5′ atg ctc tcc tgg atg tcg tc 3′ 
hcycD1 F 5′ gaa gat cgt cgc cac ctg 3′ 
hcycD1 R 5′ gac ctc ctc ctc gca ctt ct 3′ 
hCAD1 F 5′ cac tga gca tgg cgt caa 3′ 
hCAD1 R 5′ agc tgc tcc agg atg ctc 3′ .
Chromation Immunoprecipitation. Chromatin immunoprecipitation was performed as described51,52. 
Oligonucleotides were:
hCCND1prom-4129F GCTTTCCATTCAGAGGTGTGTTT (-871 from TSS)
hCCND1prom-4228R CTACCTTGACCAGTCGGTCCTT (-722 bp from TSS)
hNCLprom-4390F TCACAGAAAACCTCGCACAGA (-610 bp from TSS)
hNCLprom-4524R CCGTTGGCCCTTTTGGA (-476 bp from TSS).
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